PMID: 8611450Apr 1, 1996Paper

Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia

British Journal of Haematology
A OsterborgH Mellstedt

Abstract

The humanized CD52 monoclonal antibody Campath-1H was used as first-line therapy in nine patients with progressive chronic lymphocytic leukaemia (CLL). Intravenous (n = 5) or subcutaneous (n = 4) injections (up to 30 mg/inj.) were given three times a week for a maximum of 18 weeks. Three patients achieved a complete remission (CR) and five patients a partial remission (PR) (response rate 89%). CLL cells were cleared from blood in all patients and from the bone marrow in seven patients. The response duration time was 8 + -24+ months. Adverse events were mild except for one patient who developed CMV pneumonitis. All patients developed lymphocytopenia (B and T cells) but other haematological toxicities were negligible. Campath-1H is a highly effective and well-tolerated agent in patients with previously untreated CLL and further studies are warranted.

Citations

Aug 31, 2002·Hematological Oncology·Gerassimos A PangalisMaria K Angelopoulou
Sep 28, 2005·Cancer Immunology, Immunotherapy : CII·Bruce D Cheson
Apr 4, 2009·Targeted Oncology·Alfonso Quintás-Cardama, Susan O'Brien
Jan 1, 2008·Current Hematologic Malignancy Reports·Carmen Diana SchweighoferClemens-Martin Wendtner
Dec 15, 2010·Current Hematologic Malignancy Reports·Xavier C BadouxWilliam G Wierda
Jan 5, 2002·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·M J Keating
Jun 8, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Stanley I MartinLindsey R Baden
Apr 2, 2003·Cancer Biotherapy & Radiopharmaceuticals·Huib M Vriesendorp, Francine J Vriesendorp
Nov 21, 2000·Current Opinion in Oncology·J M Flynn, J C Byrd
Jul 10, 1999·Current Opinion in Hematology·W G Wierda, T J Kipps
Jan 11, 2005·British Journal of Haematology·S Paneesha, D W Milligan
May 11, 2002·Stem Cells·Athena CountouriotisKathleen M Sakamoto
Jul 10, 2010·OncoTargets and Therapy·Carmen Diana Schweighofer, Clemens-Martin Wendtner
Feb 23, 2011·Therapeutics and Clinical Risk Management·Jeffrey Bryan, Gautam Borthakur
Jun 7, 2003·Drugs·James E Frampton, Antona J Wagstaff
Aug 28, 2002·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Claire Dearden
Feb 5, 2005·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Tadeusz Robak
Nov 17, 2009·Drugs·Tadeusz RobakPawel Robak
Dec 4, 2012·Mediterranean Journal of Hematology and Infectious Diseases·Annamaria Nosari
Feb 7, 2007·Future Oncology·Danelle F James, Thomas J Kipps
Nov 26, 2002·Seminars in Hematology·Martin S Tallman
Dec 30, 1998·Leukemia & Lymphoma·B K Link, G J Weiner
Jan 31, 2008·Leukemia & Lymphoma·David HuiLaurie Sehn
Apr 23, 2004·Leukemia & Lymphoma·Tadeusz Robak
Aug 1, 2002·Leukemia & Lymphoma·Steven L McCuneDavid A Rizzieri
May 10, 2002·Leukemia & Lymphoma·Adam J BassDavid A Rizzieri
Sep 21, 2011·Expert Review of Anticancer Therapy·Samantha Jaglowski, Jeffrey A Jones
Mar 11, 2005·Expert Review of Anticancer Therapy·Farhad Ravandi, Susan O'Brien
Apr 12, 2008·Expert Review of Anticancer Therapy·Kevin Boyd, Claire E Dearden
Jul 1, 2008·Expert Review of Anticancer Therapy·Tadeusz Robak
Nov 1, 2007·Expert Opinion on Investigational Drugs·Mohamed A Kharfan-DabajaEdgardo S Santos
Feb 25, 2009·Expert Opinion on Biological Therapy·Magda MigkouEvangelos Terpos

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.